TNC and glioblastoma: To overcome some limitations of TNC antibody-based therapy, aptamers against TNC were developed by both a SELEX approach combining GBM cells and recombinant TNC protein [133]; thus, with the precise knowledge of the target, and a cell-SELEX against GBM U251 cells and post-SELEX target identification [128].